Ionis Pharmaceuticals Inc(IONS)stock report

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Finance:
Market Cap:8500M; Shares Outstanding:140.7M; Short Interest: 6.01%

EPS and Sales:
https://finance.yahoo.com/quote/IONS/financials?p=IONS

Date EPS % last year % last quarter
2018.12.31 2.09 1293.33% 733.33%
2019.3.31 0.98 317.78% -53.11%
2019.6.30 0.62 306.67% -36.73%
2019.9.30 0.81 345.45% 30.65%

 

Date Sales % last year % last quarter
2018.12.31 600M 16.63% 47.06%
2019.3.31 297M 105.80% -50.50%
2019.6.30 461M 75.85% 55.22%
2019.9.30 629M 54.31% 36.44%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=IONS&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/IONS/institutional-ownership/

2019.01.02:
Total institutions: 434,Reduced 2
Shares hold: 131000k shares.Reduced 1019.6k
shares% hold: 92.86%,decreased by 0.72%

Analyst Ratings:
https://www.tipranks.com/stocks/IONS/price-targe

Leave a Reply